Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Southern California
Study ID
NCT00025181
Phase
PHASE1
Status
Completed

Conditions

  • Intraocular Melanoma
  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • MART-1 antigen — BIOLOGICAL
  • gp100 antigen — BIOLOGICAL
  • incomplete Freund's adjuvant — BIOLOGICAL
  • ipilimumab — BIOLOGICAL
  • tyrosinase peptide — BIOLOGICAL
  • adjuvant therapy — PROCEDURE

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy and vaccine therapy in treating patients who have stage III or stage IV melanoma that has been removed during surgery.

Key Dates

Start date
Oct 31, 2001
Status verified
May 2014
Primary completion
Jan 31, 2003
Completion
Jun 30, 2005

Study Design

Enrollment
19 participants (actual)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
USC/Norris Comprehensive Cancer Center and HospitalLos AngelesCalifornia90089-

Find similar trials in Los Angeles, CA

By research site
USC/Norris Comprehensive Cancer Center and Hospital· Los Angeles, CA

Related Studies